Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection

• Published in: Vaccine 2021-09, Vol.39 (39), p.5580-5588
• Main Authors: Hassan, Adam S., Perera, Dilhan J., Ward, Brian J., Ndao, Momar
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Cathepsin B; Chemokines; Chronic illnesses; Chronic infection; Cytokines; Drug dosages; Eggs; Enzymes; Immunization; Immunoglobulin G; Infections; Lymphocytes T; Morphology; Murine challenge; Parasites; Parasitic diseases; Praziquantel; Salmonella; Salmonella Typhimurium; Schedules; Schistosoma mansoni; Schistosomiasis; Splenocytes; Therapeutic; Tropical diseases; Vaccine; Vaccines; Vectors; Worms; YS1646
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2021.08.031

Schistosomiasis is an important fresh-water-borne parasitic disease caused by trematode worms of the genus Schistosoma. With > 250 million people infected worldwide and approximately 800 million people at risk, the World Health Organization considers schistosomiasis to be the most important human helminth infection. Several prophylactic non-living vaccines are in pre-clinical and clinical development, but only one has been assessed for therapeutic effect in an animal model with modest results. Live attenuated Salmonella have multiple potential advantages as vaccine vectors. We have engineered an attenuated Salmonella enterica Typhimurium strain (YS1646) to produce a vaccine that targets the parasite digestive enzyme Cathepsin B (CatB). A multi-modality immunization schedule was used in chronically infected mice that included three oral (PO) doses of this CatB-bearing YS1646 strain on days one, three, and five as well as an intramuscular (IM) dose of recombinant CatB on day one. Parasite burden (worm count, intestinal and liver egg numbers) were 46.5 – 50.3% lower than in control animals 1 month post-vaccination and relative reductions further increased to 63.9 – 73.3% at 2 months. Serum anti-CatB IgG increased significantly after vaccination with the development of a more balanced TH1/TH2 pattern of response (ie: a shift in the IgG1:IgG2c ratio). Compared to control animals, a broad and robust CatB-specific cytokine/chemokine response was seen in splenocytes isolated 1 month post-vaccination. A vaccine that has both prophylactic and therapeutic activity would be ideal for use in conjunction with mass treatment campaigns with praziquantel in schistosome-endemic countries.